INTEGRATED THERAPEUTIC STRATEGIES AND PERSONALIZED APPROACHES IN THE MANAGEMENT OF LUMINAL B HER2-NEGATIVE BREAST CANCER: A CLINICAL-STATISTICAL ANALYSIS

Breast cancer (BC) remains a leading cause of female morbidity and mortality globally. Modern management has shifted from a "one-size-fits-all" approach to molecular-subtype-driven personalized therapy. This study evaluates the clinical efficacy of dose-dense neoadjuvant chemotherapy (NACT) combined with targeted hormonal maintenance in patients with Luminal B HER2-negative breast cancer (stages IIA-IIIB). Analyzing a cohort of 84 patients, we assessed the objective response rate (ORR) and the frequency of pathological complete response (pCR). Statistical analysis using Student's t-test and $\chi^2$ criteria demonstrated that the integration of taxane-based dose-dense regimens significantly improves surgical outcomes compared to standard FEC protocols ($p < 0.05$). The findings emphasize the necessity of tailoring systemic therapy based on Ki-67 proliferation indices and lymphovascular invasion markers to optimize long-term survival.

Перевод пока недоступен